SGHT
Closed
Sight Sciences Inc
4.07
-0.06 (-1.45%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 4.13
Day's Range: 4.06 - 4.31
Send
sign up or login to leave a comment!
When Written:
8.67
Sight Sciences Inc is a medical technology company that specializes in developing and commercializing innovative products for the treatment of eye diseases. The company was founded in 2011 and is headquartered in Menlo Park, California.
Sight Sciences' products include the OMNI Surgical System, a device used in glaucoma surgery, and TearCare, a device used to treat dry eye disease. The company's products are designed to provide minimally invasive and effective treatment options for patients with eye diseases.
Sight Sciences has received multiple rounds of funding from investors, including venture capital firms and strategic partners. The company has also received regulatory approvals for its products in various countries, including the United States and Europe.
The company's mission is to improve the quality of life for patients with eye diseases by developing innovative and effective treatments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sight Sciences' products include the OMNI Surgical System, a device used in glaucoma surgery, and TearCare, a device used to treat dry eye disease. The company's products are designed to provide minimally invasive and effective treatment options for patients with eye diseases.
Sight Sciences has received multiple rounds of funding from investors, including venture capital firms and strategic partners. The company has also received regulatory approvals for its products in various countries, including the United States and Europe.
The company's mission is to improve the quality of life for patients with eye diseases by developing innovative and effective treatments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








